摘要
目的对比分析^(68)Ga标记前列腺特异性膜抗原(^(68)Ga-PSMA-11)与^(18)F标记氟化钠(^(18)F-NaF)PET/CT对前列腺癌骨转移病灶的检出效能。方法收集2018年1月至2021年1月行^(68)Ga-PSMA-11 PET/CT且于1周内行^(18)F-NaF PET/CT检查的已确诊为前列腺癌并怀疑有骨转移的患者,比较分析两种检测方法的病灶数、病灶最大标准化摄取值(SUVmax)及肿瘤/背景(T/B)比值。结果^(18)F-NaF PET/CT检出的骨转移灶(310个)显著高于^(68)Ga-PSMA-11 PET/CT(264个)(P<0.001);^(18)F-NaF PET检出的SUVmax[23.2(16.4,33.4)]及T/B值[7.0(4.9,9.9)]显著高于^(68)Ga-PSMA-11 PET[SUVmax:4.1(2.5,5.6);T/B:6.7(3.7,9.6)](P均<0.001)。以病灶数作为统计对象,^(18)F-NaF PET/CT的灵敏度、特异度、准确度、阳性预测值及阴性预测值分别为100.0%、92.0%、92.0%、98.7%、100.0%;^(68)Ga-PSMA-11 PET/CT的灵敏度、特异度、准确度、阳性预测值及阴性预测值分别为85.2%、94.0%、79.2%、98.9%、50.5%。结论在前列腺癌骨转移灶的检测中,^(18)F-NaF PET/CT比^(68)Ga-PSMA-11 PET/CT更具有优势。
Objective To compare the efficiency of 68 Ga-labeled prostate-specific membrane antigen(68 Ga-PSMA-11)and 18 F-labeled sodium fluoride(18 F-NaF)PET/CT in the diagnosis of bone metastasis in the patients with prostate cancer.Methods The prostate cancer patients suspected of bone metastasis who underwent 68 Ga-PSMA-11 PET/CT and 18 F-NaF PET/CT from January 2018 to January 2021 were included in this study.The number of lesions,maximum standardized uptake value(SUVmax),and tumor-to-background(T/B)ratio were compared between the two methods.Results 18 F-NaF PET/CT detected more metastases than 68 Ga-PSMA-11 PET/CT(310 vs.264,P<0.001).The median SUVmax[23.2(16.4,33.4)vs.4.1(2.5,5.6)]and median T/B ratio[7.0(4.9,9.9)vs.6.7(3.7,9.6)]of 18 F-NaF PET/CT were higher than those of 68 Ga-PSMA-11 PET/CT(all P<0.001).With the number of lesions as the indicator,the sensitivity,specificity,accuracy,positive predictive value,and negative predictive value of 18 F-NaF PET/CT were 100.0%,92.0%,92.0%,98.7%,and 100.0%respectively,and those of 68 Ga-PSMA-11 PET/CT were 85.2%,94.0%,79.2%,98.9%,and 50.5%,respectively.Conclusion 18 F-NaF PET/CT is superior to 68 Ga-PSMA-11 PET/CT in the detection of bone metastases of prostate cancer.
作者
王安波
冯丽佳
倪萍萍
何丽萌
李红梅
张伟
WANG Anbo;FENG Lijia;NI Pingping;HE Limeng;LI Hongmei;ZHANG Wei(Department of Nuclear Medicine,The First People’s Hospital of Neijiang,Neijiang,Sichuan 641000,China;Department of Nuclear Medicine,Sichuan Provincial People’s Hospital,Sichuan Academy of Medical Sciences,Chengdu 610072,China;Department of Nuclear Medicine,Affiliated Hospital of Southwest Medical University,Luzhou,Sichuan 646000,China)
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2023年第4期634-639,共6页
Acta Academiae Medicinae Sinicae
